SCHEMBL1114784

SCHEMBL1114784

CCCCCC/C=C\CCCCCCCC(=O)Cl

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.75
TSHR P16473 1/20 0.75
TERT O14746 3/20 0.68
PTPN1 P18031 3/20 0.68
PPARG P37231 3/20 0.68
PPARD Q03181 3/20 0.68
PPARA Q07869 3/20 0.68
FAAH O00519 3/20 0.68
CYP1A2 P05177 2/20 0.68
MAPT P10636 2/20 0.68
CYP2C19 P33261 2/20 0.68
BLM P54132 2/20 0.68
HSD17B10 Q99714 2/20 0.68
FABP4 P15090 2/20 0.68
KMT2A Q03164 2/20 0.68
GMNN O75496 1/20 0.68
USP2 O75604 1/20 0.68
LMNA P02545 1/20 0.68
POLB P06746 1/20 0.68
CYP2C9 P11712 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15500041 1.00 ALDH1A1 (0.75) ALDH1A1TSHRTERTPTPN1PPARG
SCHEMBL3228812 1.00 ALDH1A1 (0.75) ALDH1A1TSHRTERTPTPN1PPARG
SCHEMBL3123425 1.00 ALDH1A1 (0.75) ALDH1A1TSHRTERTPTPN1PPARG
SCHEMBL1114787 1.00 ALDH1A1 (0.75) ALDH1A1TSHRTERTPTPN1PPARG
SCHEMBL22230778 1.00 ALDH1A1 (0.75) ALDH1A1TSHRTERTPTPN1PPARG
SCHEMBL5478764 1.00 ALDH1A1 (0.75) ALDH1A1TSHRTERTPTPN1PPARG
SCHEMBL7243894 1.00 ALDH1A1 (0.75) ALDH1A1TSHRTERTPTPN1PPARG
SCHEMBL6713314 1.00 ALDH1A1 (0.75) ALDH1A1TSHRTERTPTPN1PPARG
SCHEMBL22230779 1.00 ALDH1A1 (0.75) ALDH1A1TSHRTERTPTPN1PPARG
SCHEMBL11060705 1.00 ALDH1A1 (0.75) ALDH1A1TSHRTERTPTPN1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122012182-A Method for synthesizing branched fatty acid ester of hydroxy fatty acid by taking natural oil containing hydroxy fatty acid as raw material 江南大学 2026-05-12 CN claimed
WO-2015134256-A1 COMBINATORIAL LIBRARIES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2015-09-11 WO claimed
US-20260077038-A1 LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF AKAGERA MEDICINES, INC. (US) 2026-03-19 US disclosed
US-20260069684-A1 LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF AKAGERA MEDICINES, INC. (US) 2026-03-12 US disclosed
US-20260007741-A1 LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINES AKAGERA MEDICINES, INC. (US) 2026-01-08 US disclosed
US-20250387462-A1 LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINE FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS AKAGERA MEDICINES, INC. (US) 2025-12-25 US disclosed
EP-3695850-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING A NEGATIVELY CHARGED DRUG AND A CATIONIC LIPID SAMYANG HOLDINGS CORP (KR) 2025-05-21 EP disclosed
WO-2025034764-A1 LIPIDS FOR DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS Life Technologies Corporation (US) 2025-02-13 WO disclosed
CN-118388709-B Preparation method of functional auxiliary agent for composite packaging adhesive film for main-grid-free battery assembly 苏州易昇光学材料股份有限公司 2025-02-07 CN disclosed
US-20240325525-A1 Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof AKAGERA MEDICINES, INC. (US) 2024-10-03 US disclosed
US-12064479-B2 Lipid nanoparticles for delivery of nucleic acids and methods of use thereof AKAGERA MEDICINES, INC. (US) 2024-08-20 US disclosed
US-7319157-B1 Creatine-fatty acids MULTI FORMULATIONS LTD. (CA) 2008-01-15 US disclosed
EP-1691814-A2 ANTI-INFLAMMATORY AGENTS CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) 2006-08-23 EP disclosed
EP-1252135-B1 ESTERS OF FATTY ACIDS AND JUVENOID ALCOHOLS, AND A METHOD OF THEIR PREPARATION AND USE ACAD OF SCIENCE CZECH REPUBLIC (CZ) 2005-11-16 EP disclosed
WO-2005053702-A2 ANTI-INFLAMMATORY AGENTS CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) 2005-06-16 WO disclosed
US-6734316-B2 SUCH AS ETHYL-N-(2-(4-((CIS-2-OCTADECANOYLOXYCYCLOHEXYL) METHYL)PHEYNOXY)ETHYL)CARBAMATE FOR INSECT POPULATION DENSITY CONTROL INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR (CZ) 2004-05-11 US disclosed
US-6548486-B1 New viricide compounds of the general formula: Nu-O-Fa, wherein O represents an oxygen, Nu is a nucleoside or nucleoside analogue, and Fa is an acyl group of mono-unsaturated c18-c20 fatty acid NORSK HYDRO A.S. (NO) 2003-04-15 US disclosed
US-20030028047-A1 Esters of fatty acids and juvenoid alcohols, and a method of their preparation and use INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR (CZ) 2003-02-06 US disclosed
WO-1993007163-A1 CHEMICAL COMPOUNDS NORSK HYDRO A.S. (NO) 1993-04-15 WO disclosed
EP-0350672-A1 Salts of diacyl-glycero-(di)-phosphates of L-(acyl) carnitine and of L-acyl-carnitine esters MAGIS FARMACEUTICI S.p.A. (IT) 1990-01-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260069684-A1 LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF PHOSPHO1, PLTP, SGMS1 ALDH1A1 4716/4885TSHR 4047/4885TERT 4172/4885
US-20250387462-A1 LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINE FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS CD4, MICA, LNPK ALDH1A1 4826/4885TSHR 2942/4885TERT 2630/4885
US-20030028047-A1 Esters of fatty acids and juvenoid alcohols, and a method of their preparation and use ALOX15, LIPC, CPT1A ALDH1A1 1603/4885TSHR 2373/4885TERT 247/4885
US-20260007741-A1 LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINES TLR9, TLR3, TLR8 ALDH1A1 4581/4885TSHR 3557/4885TERT 3240/4885
US-20260077038-A1 LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF PHOSPHO1, LNPK, SGMS2 ALDH1A1 4782/4885TSHR 3848/4885TERT 4009/4885
US-12064479-B2 Lipid nanoparticles for delivery of nucleic acids and methods of use thereof PHOSPHO1, PTDSS1, PTDSS2 ALDH1A1 4475/4885TSHR 4168/4885TERT 3704/4885
US-20240325525-A1 Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof PHOSPHO1, PTDSS1, PTDSS2 ALDH1A1 4475/4885TSHR 4168/4885TERT 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.